The Global Health Body Issues Concern Over Severe Shortage of Weight-Loss Jabs

Fewer than a tenth of patients who could benefit from weight-loss injections such as Wegovy can access them, caution the WHO as it publishes its inaugural recommendations on the drugs.

Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging increased and just access to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.

"Our new guidance acknowledges that obesity is a chronic disease that can be treated with holistic and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and supply-chain constraints are key barriers to broad availability to the injections that can help people shift substantial weight, notes the organization.

GLP-1 Therapy Supply Crisis

Even in the current best projected outlook, the production of such drugs would only suffice for approximately 100 million people – less than 10% of those who need them, according to the WHO.

The guideline calls on countries and companies to expand availability, by approaches like voluntary licensing.

Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.

The Way Obesity Jabs Function

GLP-1 drugs mimick a body's own hormone to delay gastric emptying, reduce hunger and boost the sense of being full so individuals eat less.

Individuals commonly start to lose weight within a few weeks of starting on the regular doses.

Evidence indicates users may put most of the weight back on a year later of halting the treatment, as their typical appetite come back.

Being above a healthy weight elevates your likelihood for experiencing medical conditions, like type 2 diabetes, heart disease, stroke, and certain malignancies.

Obesity concerns people in every country and was responsible for millions of deaths worldwide in 2024, per the WHO.